Report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app)
Stronger effects can also lead to more severe side effects and a greater need for monitoring
It is well established that patients with diabetes demonstrate higher susceptibility to pancreatic cancer and pancreatitis compared to non-diabetic individuals, and theoretically, sustained GLP-1 receptor activation induced by GLP-1RA therapy may potentially elevate pancreatic cancer risk [8]
While no absolute contraindication exists for their combined use, understanding potential pharmacodynamic interactionsparticularly regarding hypoglycemia recognition and heart rate effectsis essential for safe, effective therapy under medical supervision
reported that 1.8 mg/day liraglutide did not effectively reduce SBP compared to 4 mg/day glimepiride (a sulfonylurea) [89]
In order to measure de-glutathionylation of GAPDH, the enzyme is first glutathionylated and thus inactivated in its enzymatic function